Mereo BioPharma (MREO) Payables (2017 - 2026)

Mereo BioPharma (MREO) has 10 years of Payables data on file, last reported at $3.2 million in Q1 2026.

• Payables for Q1 2026 came in at $3.2 million, up 10.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 million (up 10.33% YoY), and the FY2025 annual result was $1.3 million, down 83.29% from the prior year.
• Payables grew to $3.2 million in Q1 2026 per MREO's latest filing, from $1.3 million in the prior quarter.
• Over five years, Payables peaked at $16.6 million in Q4 2022 and troughed at $879000.0 in Q3 2025.
• A 5-year average of $5.3 million and a median of $3.2 million in 2026 frame the typical range for Payables.
• The sharpest annual moves came in 2022 and 2025: Payables surged 393.14% in 2022, then plunged 87.96% in 2025.
• A 5-year view of Payables shows it stood at $16.6 million in 2022, then plunged by 85.88% to $2.3 million in 2023, then surged by 239.94% to $8.0 million in 2024, then tumbled by 83.29% to $1.3 million in 2025, then jumped by 142.01% to $3.2 million in 2026.
• Business Quant data shows MREO's Payables at $3.2 million in Q1 2026, $1.3 million in Q4 2025, and $879000.0 in Q3 2025.